**Background**
Protein kinase C (PKC) is a family of serine/threonine kinases that play pivotal roles in various cellular processes, including signal transduction, gene expression, and cell proliferation. Dysregulation of PKC isoforms is often associated with a wide range of pathologies, including inflammation, cardiovascular diseases, and various forms of cancer. Similarly, glycogen synthase kinase-3 (GSK-3) is a key regulator of glucose metabolism and cellular signaling, and its overactivity is linked to several metabolic and neurodegenerative disorders. Given the critical roles of these kinases in disease progression, identifying potent and selective inhibitors is essential for developing therapeutic interventions. In this context, we will introduce a cell-permeable and reversible inhibitor – Bisindolylmaleimide I.
**Definition**
Bisindolylmaleimide I (GF109203X) hydrochloride is a cell-permeable and reversible PKC inhibitor with IC50 values of 20 nM for PKCα, 17 nM for PKCβI, 16 nM for PKCβII, and 20 nM for PKCγ. Additionally, it serves as an inhibitor of GSK-3.
**In Vitro and In Vivo Studies**
The Bisindolylmaleimide I description highlights its versatility as a kinase inhibitor across multiple biological systems. In terms of Bisindolylmaleimide I in vitro activity, the compound at 5 μM inhibits α-thrombin-induced P47 phosphorylation and reduces GSK-3 activity to 25.1±4.3% in adipocyte lysates. Furthermore, concentrations ranging from 0-1 μM inhibit DNA synthesis in quiescent Swiss 3T3 cells. In the context of Bisindolylmaleimide I Cancer research, treatment with 10 μM for 24 hours inhibits the release of exosomes and microvesicles (EMV) from PC3 cells and enhances the cytotoxicity of 5-fluorouracil.
Regarding Bisindolylmaleimide I In Vivo applications, the compound has demonstrated significant efficacy in various animal models. At a dose of 0.02 mg/kg (i.p.), it reduced the levels of NLRP3, P-PKCα, and PKCα in mechanical ventilation groups. In Quinpirole-treated shrews, administration of 0-20 mg/kg (i.p.) reduced the mean frequency of induced vomiting and blocked Quinpirole-mediated ERK1/2 phosphorylation in the brainstem. For researchers seeking detailed Bisindolylmaleimide I technical information, these results underscore the compound’s potency in modulating kinase-driven inflammatory and neurological responses. In conclusion, Bisindolylmaleimide I is a potent inhibitor of PKC and GSK-3 with broad applications in cellular and systemic research.
Keywords
Bisindolylmaleimide I, 176504-36-2, GF109203X, Go 6850, Go6850, Go-6850, PKC, GSK-3, Protein kinase C, Glycogen synthase kinase-3, Glycogen synthase kinase 3, Exosome, 3T3, adipocyte, 5-fluorouracil, P47, shrews, Inhibitor, inhibitor, inhibit
References
[1] Toullec D, et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem. 1991 Aug 25;266(24):15771-81.
[2] Vetri F, et al. Impairment of neurovascular coupling in Type 1 Diabetes Mellitus in rats is prevented by pancreatic islet transplantation and reversed by a semi-selective PKC inhibitor. Brain Res. 2017 Jan 15;1655:48-54.
[3] Hers I, et al. The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Lett. 1999 Nov 5;460(3):433-6.
[4] Kosgodage US, et al. Chloramidine/Bisindolylmaleimide-I-Mediated Inhibition of Exosome and Microvesicle Release and Enhanced Efficacy of Cancer Chemotherapy. Int J Mol Sci. 2017 May 9;18(5):1007.
[5] Liu M, et al. Aerobic exercise alleviates ventilator-induced lung injury by inhibiting NLRP3 inflammasome activation. BMC Anesthesiol. 2022 Dec 1;22(1):369.
[6] Belkacemi L, et al. Signal transduction pathways involved in dopamine D2 receptor-evoked emesis in the least shrew (Cryptotis parva). Auton Neurosci. 2021 Jul;233:102807.